Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of cardiovascular risks with fingolimod in patients with early cardiovascular events
2014-001241-24Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Incidence of selected cardiovascular events over the course of the study. Started Jul 2014; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-001241-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001241-24.